Connect to End Cancer launches at South By Southwest 2017 Conference and Festivals
HOUSTON ― The University of Texas MD Anderson Cancer Center, in collaboration with the AT&T Foundry for Connected Health, will launch Connect to End Cancer on Sunday, March 12, 2017 at the South by Southwest® Conference and Festivals (SXSW®) in Austin, Texas. The inaugural event will provide education, exposure and potential development support to entrepreneurs as well as encourage collaboration among innovators, industry executives...
Mulva Family Foundation Contributes $75 Million to Fund Patient Care and Research in Neuroscience at UT Austin, Melanoma and Prostate Cancer at MD Anderson
James and Miriam Mulva and the Mulva Family Foundation have donated $50 million to advance neuroscience at The University of Texas at Austin...
Older women with breast cancer report better cosmetic satisfaction with less radiation, less surgery
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The...
Image-guided biopsy identifies patients who achieve pathologic complete response after neoadjuvant therapy
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). Should the findings be replicated in future studies, this research would be the first indication that as the field moves toward more selective, personalized treatment...
MD Anderson affirms Surgeon General’s conclusions on e-cigarette use among youth and young adults
The University of Texas MD Anderson Cancer Center fully supports the United States Surgeon General’s call to action to prevent the use of...
Ronald A. DePinho, M.D., on passage of the 21st Century Cures Act
With strong bipartisan support, the U.S. House and Senate have passed transformative legislation, the 21st Century Cures Act, which will support...
Nivolumab with chemotherapy improves response, survival in AML study patients
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival...
Research shows patients ineligible for studies may benefit from trial participation
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility...
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after...